March 2026
-
Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta…
-
Press release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
-
Press release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence…
-
Press release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipelineProposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,…
-
Story People and Culture
Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech -
Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativaCosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring…
-
Story From Our Labs
Bringing proteins together to take cancer apart -
Story People and Culture
Turning personal experience into purpose-driven careers -
Story People and Culture
Supercharging R&D: How AI helps us to bring medicines to patients faster -
Press release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General MeetingShareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as…
-
Press release
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gutDie Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹Die…